GlassScriptPhysician profile
Bridget A Green
NPI 1356542500
$4,755.74
in general payments reported to CMS, 2019-2025
26 companies · $762 in 2025
The $762 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $226 · 2021: $582 · 2022: $761 · 2023: $764 · 2024: $903 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.77 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,374.07 | 2019-2025 | |
| Pfizer INC. | $650.88 | 2019-2025 | |
| Abbvie INC. | $329.83 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $288.42 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $272.00 | 2022-2024 | |
| Janssen Biotech, INC. | $268.73 | 2021-2025 | Tremfya |
| Genzyme Corporation | $257.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.16 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $210.41 | 2019-2024 | Libtayo, Dupixent |
| Ucb, INC. | $157.37 | 2019-2022 | |
| Lilly USA, LLC | $155.80 | 2019-2025 | Ebglyss, Taltz |
| Amgen INC. | $125.04 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $96.09 | 2019-2025 | Adbry |
| Fresenius Kabi USA, LLC | $79.86 | 2023-2024 | Idacio |
| Organon LLC | $60.49 | 2023-2024 | Hadlima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $29.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.27 | 2023 | Spevigo |
| Genentech USA, INC. | $21.19 | 2019 | |
| Epi Health, LLC | $20.71 | 2019 | |
| Incyte Corporation | $19.47 | 2021 | |
| Galderma Laboratories, L.P. | $18.27 | 2022 | |
| Journey Medical Corporation | $17.26 | 2021 | |
| Almirall LLC | $16.94 | 2023 | Seysara |
| Dusa Pharmaceuticals, INC. | $14.86 | 2019 | |
| Dermavant Sciences, INC. | $13.78 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.